{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:29:45Z","timestamp":1789662585865,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"DOI":"10.7759\/cureus.48865","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T05:04:13Z","timestamp":1700111053000},"source":"Crossref","is-referenced-by-count":25,"title":["Lipoproteins and Their Effects on the Cardiovascular System"],"prefix":"10.7759","author":[{"given":"Pratyush","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant","family":"Ingole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-4526(08)60107-2","article-title":"Dietary fatty acids, lipoproteins, and cardiovascular disease","volume":"36","author":"Mcnamara DJ","year":"1992","unstructured":"Mcnamara DJ. Dietary fatty acids, lipoproteins, and cardiovascular disease. Adv Food Nutr Res. 1992, 36:253-351. 10.1016\/S1043-4526(08)60107-2","journal-title":"Adv Food Nutr Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.10.4.497","article-title":"Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease","volume":"10","author":"Despr\u00e9s JP","year":"1990","unstructured":"Despr\u00e9s JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis. 1990, 10:497-511. 10.1161\/01.atv.10.4.497","journal-title":"Arteriosclerosis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/65.5.1655S","article-title":"Effects of dietary fatty acids on lipoproteins and cardiovascular disease risk: summary","volume":"65","author":"Schaefer EJ","year":"1997","unstructured":"Schaefer EJ. Effects of dietary fatty acids on lipoproteins and cardiovascular disease risk: summary. Am J Clin Nutr. 1997, 65:1655S-1656S. 10.1093\/ajcn\/65.5.1655S","journal-title":"Am J Clin Nutr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3940","article-title":"Lipids, lipoproteins, and cardiovascular disease: clinical pharmacology now and in the future","volume":"101","author":"Chait A","year":"2016","unstructured":"Chait A, Eckel RH. Lipids, lipoproteins, and cardiovascular disease: clinical pharmacology now and in the future. J Clin Endocrinol Metab. 2016, 101:804-814. 10.1210\/jc.2015-3940","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.25220\/WNJ.V04.i2.0010","article-title":"Association between apolipoprotein B and dietary fibers","volume":"4","author":"Gunawan AD","year":"2021","unstructured":"Gunawan AD, Bardosono S, Mudjihartini N. Association between apolipoprotein B and dietary fibers. World Nutr J. 2021, 4:73-83. 10.25220\/WNJ.V04.i2.0010","journal-title":"World Nutr J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/784536","article-title":"The chylomicron: relationship to atherosclerosis","volume":"2012","author":"Tomkin GH","year":"2012","unstructured":"Tomkin GH, Owens D. The chylomicron: relationship to atherosclerosis. Int J Vasc Med. 2012, 2012:784536. 10.1155\/2012\/784536","journal-title":"Int J Vasc Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108517","article-title":"The role of atherogenic lipoproteins in diabetes: molecular aspects and clinical significance","volume":"37","author":"Banerjee Y","year":"2023","unstructured":"Banerjee Y, Patti AM, Giglio RV, et al.. The role of atherogenic lipoproteins in diabetes: molecular aspects and clinical significance. J Diabetes Complicat. 2023, 37:108517. 10.1016\/j.jdiacomp.2023.108517","journal-title":"J Diabetes Complicat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon DJ","year":"1989","unstructured":"Gordon DJ, Probstfield JL, Garrison RJ, et al.. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989, 79:8-15. 10.1161\/01.cir.79.1.8","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90562-F","article-title":"High-density lipoprotein, low-density lipoprotein and coronary artery disease","volume":"66","author":"Wilson PW","year":"1990","unstructured":"Wilson PW. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990, 66:7-10. 10.1016\/0002-9149(90)90562-F","journal-title":"Am J Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.125401","article-title":"Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels","volume":"84","author":"Hausenloy DJ","year":"2008","unstructured":"Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J. 2008, 84:590-598. 10.1136\/hrt.2007.125401","journal-title":"Postgrad Med J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212525","article-title":"High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease","volume":"7","author":"Kosmas CE","year":"2018","unstructured":"Kosmas CE, Martinez I, Sourlas A, et al.. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018, 7:212525. 10.7573\/dic.212525","journal-title":"Drugs Context"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.12.2.187","article-title":"Low density lipoprotein particle size and coronary artery disease","volume":"12","author":"Campos H","year":"1992","unstructured":"Campos H, Genest JJ Jr, Blijlevens E, et al.. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992, 12:187-195. 10.1161\/01.atv.12.2.187","journal-title":"Arterioscler Thromb"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci154","article-title":"Low-density lipoprotein size and cardiovascular risk assessment","volume":"99","author":"Rizzo M","year":"2006","unstructured":"Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006, 99:1-14. 10.1093\/qjmed\/hci154","journal-title":"QJM"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.05.914","article-title":"Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets","volume":"235","author":"Toth PP","year":"2014","unstructured":"Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis. 2014, 235:585-591. 10.1016\/j.atherosclerosis.2014.05.914","journal-title":"Atherosclerosis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/10408399509527689","article-title":"Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation","volume":"35","author":"Frei B","year":"1995","unstructured":"Frei B. Cardiovascular disease and nutrient antioxidants: role of low-density lipoprotein oxidation. Crit Rev Food Sci Nutr. 1995, 35:83-98. 10.1080\/10408399509527689","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.64.6.1174","article-title":"Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease","volume":"64","author":"Tatami R","year":"1981","unstructured":"Tatami R, Mabuchi H, Ueda K, et al.. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981, 64:1174-1184. 10.1161\/01.cir.64.6.1174","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V971277","article-title":"Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients","volume":"9","author":"Shoji T","year":"1998","unstructured":"Shoji T, Nishizawa Y, Kawagishi T, et al.. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol. 1998, 9:1277-1284. 10.1681\/ASN.V971277","journal-title":"J Am Soc Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92734-6","article-title":"Intermediate-density lipoproteins and progression of coronary artery diseases in hypercholesterolaemic men","volume":"330","author":"Krauss RM","year":"1987","unstructured":"Krauss RM, Williams PT , Brensike J, et al.. Intermediate-density lipoproteins and progression of coronary artery diseases in hypercholesterolaemic men. Lancet. 1987, 330:62-66. 10.1016\/S0140-6736(87)92734-6","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.065","article-title":"Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition\u00a0of\u00a0APOC-III","volume":"69","author":"Pechlaner R","year":"2017","unstructured":"Pechlaner R, Tsimikas S, Yin X, et al.. Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition\u00a0of\u00a0APOC-III. J Am Coll Cardiol. 2017, 69:789-800. 10.1016\/j.jacc.2016.11.065","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(73)90138-0","article-title":"On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein","volume":"326","author":"Eisenberg S","year":"1973","unstructured":"Eisenberg S, Bilheimer DW, Levy RI, Lindgren FT. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. Biochim Biophys Acta Lipids Lipid Metab. 1973, 326:361-377. 10.1016\/0005-2760(73)90138-0","journal-title":"Biochim Biophys Acta Lipids Lipid Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.156.1.230","article-title":"Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein","volume":"156","author":"de Beer FC","year":"1982","unstructured":"de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med. 1982, 156:230-242. 10.1084\/jem.156.1.230","journal-title":"J Exp Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.09.010","article-title":"Small dense LDL: an emerging risk factor for cardiovascular disease","volume":"414","author":"Hirayama S","year":"2012","unstructured":"Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012, 414:215-224. 10.1016\/j.cca.2012.09.010","journal-title":"Clin Chim Acta"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"Ldl particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management","volume":"1","author":"Cromwell WC","year":"2007","unstructured":"Cromwell WC, Otvos JD, Keyes MJ, et al.. Ldl particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management. J Clin Lipidol. 2007, 1:583-592. 10.1016\/j.jacl.2007.10.001","journal-title":"J Clin Lipidol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0b013e318057d4c9","article-title":"Cardiovascular disease under the influence of excess visceral fat","volume":"6","author":"Despr\u00e9s JP","year":"2007","unstructured":"Despr\u00e9s JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 2007, 6:51-59. 10.1097\/HPC.0b013e318057d4c9","journal-title":"Crit Pathw Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030636","article-title":"Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal","volume":"88","author":"Sacks FM","year":"2003","unstructured":"Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003, 88:4525-4532. 10.1210\/jc.2003-030636","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference BA","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38:2459-2472. 10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2010.222","article-title":"HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms","volume":"8","author":"Navab M","year":"2011","unstructured":"Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011, 8:222-232. 10.1038\/nrcardio.2010.222","journal-title":"Nat Rev Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61217-4","article-title":"High density lipoproteins and cardiovascular disease","volume":"384","author":"Rader DJ","year":"2014","unstructured":"Rader DJ, Hovingh GK. High density lipoproteins and cardiovascular disease. Lancet. 2014, 384:618-625. 10.1016\/S0140-6736(14)61217-4","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1658","article-title":"HDL as a target in the treatment of atherosclerotic cardiovascular disease","volume":"4","author":"Linsel-Nitschke P","year":"2005","unstructured":"Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005, 4:193-205. 10.1038\/nrd1658","journal-title":"Nat Rev Drug Discov"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2002.85","article-title":"The role of high density lipoproteins in thrombosis","volume":"2","author":"Cuchel M","year":"2002","unstructured":"Cuchel M, Rader DJ. The role of high density lipoproteins in thrombosis. ScientificWorldJournal. 2002, 2:89-95. 10.1100\/tsw.2002.85","journal-title":"ScientificWorldJournal"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084300","article-title":"Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL)","volume":"23","author":"Huang JK","year":"2022","unstructured":"Huang JK, Lee HC. Emerging evidence of pathological roles of very-low-density lipoprotein (VLDL). Int J Mol Sci. 2022, 23:4300. 10.3390\/ijms23084300","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler PR","year":"2017","unstructured":"Lawler PR, Akinkuolie AO, Chu AY, et al.. Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol. J Am Heart Assoc. 2017, 6:e005549. 10.1161\/JAHA.117.005549","journal-title":"J Am Heart Assoc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0847-z","article-title":"Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease","volume":"18","author":"Vaziri ND","year":"2014","unstructured":"Vaziri ND. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol. 2014, 18:265-268. 10.1007\/s10157-013-0847-z","journal-title":"Clin Exp Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard BG","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014, 384:626-635. 10.1016\/S0140-6736(14)61177-6","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(87)90020-7","article-title":"Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study","volume":"65","author":"Simons LA","year":"1987","unstructured":"Simons LA, Dwyer T, Simons J, et al.. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 1987, 65:181-189. 10.1016\/0021-9150(87)90020-7","journal-title":"Atherosclerosis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg HN","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, et al.. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021, 42:4791-4806. 10.1093\/eurheartj\/ehab551","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7036.935","article-title":"Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years","volume":"312","author":"Weintraub MS","year":"1996","unstructured":"Weintraub MS, Grosskopf I, Rassin T, et al.. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996, 312:935-939. 10.1136\/bmj.312.7036.935","journal-title":"BMJ"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.09.019","article-title":"Regulation of chylomicron production in humans","volume":"1821","author":"Xiao C","year":"2012","unstructured":"Xiao C, Lewis GF. Regulation of chylomicron production in humans. Biochim Biophys Acta. 2012, 1821:736-746. 10.1016\/j.bbalip.2011.09.019","journal-title":"Biochim Biophys Acta"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-013-0110-5","article-title":"Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations","volume":"44","author":"Mann S","year":"2014","unstructured":"Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014, 44:211-221. 10.1007\/s40279-013-0110-5","journal-title":"Sports Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0b013e31816722a9","article-title":"Vigorous exercise, fitness and incident hypertension, high cholesterol, and diabetes","volume":"40","author":"Williams PT","year":"2008","unstructured":"Williams PT. Vigorous exercise, fitness and incident hypertension, high cholesterol, and diabetes. Med Sci Sports Exerc. 2008, 40:998-1006. 10.1249\/MSS.0b013e31816722a9","journal-title":"Med Sci Sports Exerc"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2165\/00007256-199928050-00002","article-title":"Physical activity and high density lipoprotein cholesterol levels: what is the relationship?","volume":"28","author":"Kokkinos PF","year":"1999","unstructured":"Kokkinos PF, Fernhall B. Physical activity and high density lipoprotein cholesterol levels: what is the relationship?. Sports Med. 1999, 28:307-314. 10.2165\/00007256-199928050-00002","journal-title":"Sports Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5406-7","article-title":"Lipid-lowering drugs","volume":"63","author":"Pahan K","year":"2006","unstructured":"Pahan K. Lipid-lowering drugs. Cell Mol Life Sci. 2006, 63:1165-1178. 10.1007\/s00018-005-5406-7","journal-title":"Cell Mol Life Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins \u2014 mechanisms and consequences","volume":"4","author":"Be\u0142towski J","year":"2009","unstructured":"Be\u0142towski J, W\u00f3jcicka G, Jamroz-Wi\u015bniewska A. Adverse effects of statins \u2014 mechanisms and consequences. Curr Drug Saf. 2009, 4:209-228. 10.2174\/157488609789006949","journal-title":"Curr Drug Saf"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.005","article-title":"Statins, cardiovascular disease, and drug safety","volume":"97","author":"Gotto AM Jr","year":"2006","unstructured":"Gotto AM Jr. Statins, cardiovascular disease, and drug safety. Am J Cardiol. 2006, 97:S3-S5. 10.1016\/j.amjcard.2005.12.005","journal-title":"Am J Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage J","year":"2007","unstructured":"Armitage J. The safety of statins in clinical practice. Lancet. 2007, 370:1781-1790. 10.1016\/S0140-6736(07)60716-8","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","author":"Argo CK","year":"2008","unstructured":"Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither?. Hepatology. 2008, 48:662-669. 10.1002\/hep.22402","journal-title":"Hepatology"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen KE","year":"2005","unstructured":"Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005, 165:2671-2676. 10.1001\/archinte.165.22.2671","journal-title":"Arch Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/177395-lipoproteins-and-their-effects-on-the-cardiovascular-system","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:24Z","timestamp":1707509484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/177395-lipoproteins-and-their-effects-on-the-cardiovascular-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.48865","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,15]]}}}